Clinical Trial Update: Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas [Phase 2]

View source ↗

Summary

Phase IIa trial evaluating redirected autologous T cells engineered with anti-CD19 attached to TCRz and 4-signaling domains in CD19+ B-cell lymphomas; completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Redirected autologous T cells engineered to contain anti-CD19 attached to TCRz and 4-signaling domains

Snippet

Sponsor: University of Pennsylvania | Conditions: Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas | Phase 2 | Status: COMPLETED | Results posted: 2020-10-05